Reegan Burnell-Clarke: Pegcetacoplan and the Evolving Treatment Landscape of PNH
Reegan Burnell-Clarke, Commissioning Editor at Taylor and Francis Group, shared a post on LinkedIn about a recent article by Tze Wei Chan et al, published in Expert Review of Hematology, adding:
”Pegcetacoplan is becoming an important part of the conversation in paroxysmal nocturnal hemoglobinuria (PNH), and this 2024 drug profile published in Expert Review of Hematology offers a timely look at why.
The paper explores how this C3 inhibitor is reshaping treatment thinking, particularly for patients with ongoing anemia, transfusion burden, or suboptimal response to existing therapies.
What makes this profile worth reading is its balanced view. It highlights the clinical promise of pegcetacoplan, including improvements in hemoglobin and fatigue, and the convenience of self-administered subcutaneous dosing, while also pointing to the unanswered questions around breakthrough hemolysis, long-term positioning, and cost-effectiveness.
For anyone following advances in rare hematological conditions, this is a strong snapshot of where pegcetacoplan stands today and where the next wave of evidence could take PNH treatment.”
Title: Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria
Authors: Tze Wei Chan, Hein Than, Tertius Tuy, Yeow Tee Goh
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 28, 2026, 03:50ZhiChao (David) Yang: MedicalBench Tests AI in Clinical Reasoning
-
Oct 28, 2026, 03:46Phillip Smith: Strengthening Partnerships and Connections in the Rare Disease and Hemophilia Communities
-
Oct 28, 2026, 03:42Ashley Bradley: Understanding Jalen Hurts’ Diagnosis: DVT and Venous Thromboembolism in Athletes
-
Oct 28, 2026, 03:39Gregory Denomme: Petz and Garratty’s Immune Hemolytic Anemias Third Edition
-
Oct 28, 2026, 03:38Ahmed Alotaibi: Monoclonal Antibodies Challenge Routine Pretransfusion Testing
-
Oct 28, 2026, 03:32Wolfgang Miesbach: Should Prophylaxis in Type 3 VWD Follow the Bleeding Phenotype?
-
Oct 28, 2026, 03:25Owen McCarty: Exploring Platelet Polyphosphates in Coagulation Under Flow
-
Oct 28, 2026, 03:19Arwa Z. Al-Riyami: Key Takeaways from the Blood Conference in Auckland
-
Oct 28, 2026, 03:14Kristopher Jonas: The Ethical Case for Compensated Plasma Donation